Mabfilin and Fabfilin - New antibody-scaffold fusion formats for multispecific targeting concepts.
Sign Up to like & getrecommendations! Published in 2018 at "Protein expression and purification"
DOI: 10.1016/j.pep.2018.04.013
Abstract: Protein based binding molecules have a broad applicability from therapeutic to technical use. Monoclonal antibodies represent the major class of this type of agents complemented by innovative approaches using scaffold proteins with tailor-made properties. Various… read more here.
Keywords: scaffold fusion; antibody; antibody scaffold; mabfilin fabfilin ... See more keywords
The discovery of a new antibody for BRIL-fused GPCR structure determination
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-68355-x
Abstract: G-protein-coupled receptors (GPCRs)—the largest family of cell-surface membrane proteins—mediate the intracellular signal transduction of many external ligands. Thus, GPCRs have become important drug targets. X-ray crystal structures of GPCRs are very useful for structure-based drug… read more here.
Keywords: bril; antibody; structure determination; structure ... See more keywords
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0407
Abstract: Sacituzumab govitecan (SG) is a new antibody-drug conjugate directed against the cell-surface antigen Trop-2. Characteristics of the linker connecting the payload SN-38 to the antibody allows SG to kill tumor cells expressing Trop-2 and also the adjacent tumor… read more here.
Keywords: new antibody; sacituzumab govitecan; drug conjugate; antibody drug ... See more keywords